ଡୁଭେଲିସିବ

ଡୁଭେଲିସିବ
Clinical data
Pronunciation	DOO-VE-LI-SIB
Trade names	Copiktra
AHFS/Drugs.com	monograph
MedlinePlus	a618056
data	US DailyMed: Duvelisib;
Routes of; administration	By mouth (capsules)
Legal status
Legal status	US: ℞-only ; EU: Rx-only ;
Pharmacokinetic data
Metabolism	mainly metabolized by CYP3A4
Onset of action	1-2 hours after initial administration
Elimination half-life	5.2 to 10.9 hours
Excretion	Feces (79%), urine (14%)
Identifiers
	IUPAC name 8-Chloro-2-phenyl-3-[(1S)-1-(3H-purin-6-ylamino)ethyl]-1(2H)-isoquinolinone;
ECHA InfoCard	100.245.560
Chemical and physical data
Formula	C22H17ClN6O
Molar mass	୪୧୬.୮୭ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H](C1=CC2=C(C(=CC=C2)Cl)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5;

ଡୁଭେଲିସିବ (ଇଂରାଜୀ ଭାଷାରେ Duvelisib), କୋପିକଟ୍ରା ଏହାର ଏକ ବେପାର ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା କ୍ରନିକ୍ ଲିମ୍ଫୋସାଇଟିକ ଲିଉକେମିଆ (CLL), ଛୋଟ ଲିମ୍ଫୋସାଇଟିକ ଲିମ୍ଫୋମା (SLL) ଏବଂ ଫୋଲିକୁଲାର ଲିମ୍ଫୋମା ରୋଗମାନଙ୍କର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୨] ଯେତେବେଳେ ଅନ୍ୟ ଚିକିତ୍ସା ବିଫଳ ହୁଏ ସେତେବେଳେ ଏହା ବ୍ୟବହୃତ ହୁଏ । ଏହା ପାଟିରେ ଦିଆଯାଏ ।

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ତରଳ ଝାଡ଼ା, ସ୍ୱଳ୍ପ ରକ୍ତ କଣିକା, ରାସ, ଥକାପଣ, ଜ୍ୱର, ଯକୃତ ସମସ୍ୟା ଏବଂ ମାଂସପେଶୀ ଯନ୍ତ୍ରଣା ହୋଇପାରେ ।^[୨] ଅନ୍ୟାନ୍ୟ ଗମ୍ଭୀର ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଫୁସଫୁସର ପ୍ରଦାହ, ଅନୁର୍ବରତା ଏବଂ ସଂକ୍ରମଣ ହୋଇପାରେ । ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ଶିଶୁର କ୍ଷତି ହୋଇପାରେ । ଏହା ପିଆଇ୩କେଓ ଏବଂ ପିଆଇ୩କେୱାଇର (PI3Kδ ଏବଂ PI3Kγ) ଏକ ଦ୍ୱୈତ ପ୍ରତିବନ୍ଧକ ।

୨୦୧୮ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏବଂ ୨୦୨୧ ରେ ୟୁରୋପରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ଡୁଭେଲିସିବ୍ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୨] ^[୩] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୪ ସପ୍ତାହର ଚିକିତ୍ସା ଖର୍ଚ୍ଚ ୨୦୨୧ ସୁଦ୍ଧା ପ୍ରାୟ ୧୭,୨୦୦ ଡଲାର ଥିଲା ।^[୪]

ଆଧାର

↑ "Full prescribing information: COPIKTRA (duvelisib)" (PDF). U.S. Food and Drug Administration. Archived (PDF) from the original on 11 February 2020. Retrieved 23 October 2018.
↑ ^୨.୦ ^୨.୧ ^୨.୨ "Duvelisib Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Archived from the original on 28 February 2019. Retrieved 28 February 2019.
↑ "Copiktra". Archived from the original on 16 December 2021. Retrieved 27 December 2021.
↑ "Copiktra Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 27 January 2021. Retrieved 27 December 2021.

[1] "Full prescribing information: COPIKTRA (duvelisib)" (PDF). U.S. Food and Drug Administration. Archived (PDF) from the original on 11 February 2020. Retrieved 23 October 2018.

[AHFS2019-2] ୨.୦ ^୨.୧ ^୨.୨ "Duvelisib Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Archived from the original on 28 February 2019. Retrieved 28 February 2019.

[EPAR2021-3] "Copiktra". Archived from the original on 16 December 2021. Retrieved 27 December 2021.

[4] "Copiktra Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 27 January 2021. Retrieved 27 December 2021.

[୨]

[୧]

[୩]

[୪]

Clinical data

Pronunciation	DOO-VE-LI-SIB
Trade names	Copiktra
AHFS/Drugs.com	monograph
MedlinePlus	a618056
data	US DailyMed: Duvelisib
Routes of administration	By mouth (capsules)
Legal status
Legal status	US: ℞-only EU: Rx-only
Pharmacokinetic data
Metabolism	mainly metabolized by CYP3A4^[୧]
Onset of action	1-2 hours after initial administration
Elimination half-life	5.2 to 10.9 hours
Excretion	Feces (79%), urine (14%)
Identifiers
IUPAC name 8-Chloro-2-phenyl-3-[(1S)-1-(3H-purin-6-ylamino)ethyl]-1(2H)-isoquinolinone
ECHA InfoCard	100.245.560
Chemical and physical data
Formula	C₂₂H₁₇ClN₆O
Molar mass	୪୧୬.୮୭ g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES C[C@@H](C1=CC2=C(C(=CC=C2)Cl)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5